THE MEDICINES CO
PharmaTHE MEDICINES CO is a pharmaceutical company focused on Cardiovascular, Infectious Disease, Dermatology.
THE MEDICINES CO at a Glance
- Strong track record with 80% execution quality across 30 trials
- Fast trial execution (14 months median completion)
Upcoming FDA Decisions
Full Calendar →THE MEDICINES CO's Key Drugs
THE MEDICINES CO's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
THE MEDICINES CO's Recent FDA Approvals
New NDA/BLA approvals for THE MEDICINES CO over the last two years — novel drugs only, excluding generics and label supplements.
THE MEDICINES CO's Therapeutic Areas
THE MEDICINES CO's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.
THE MEDICINES CO's Top Competitors
THE MEDICINES CO's closest competitors by therapeutic-area and drug-target overlap include Merck, B BRAUN, and PHARMACIA AND UPJOHN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
THE MEDICINES CO Pipeline Snapshot
THE MEDICINES CO has 20 active clinical programs from ClinicalTrials.gov — 6 Phase 3, 5 Phase 2 and 9 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 9/12 completed
- • Speed: 14 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2006-05-22
- Latest
- 2018-10-03
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges